1211540-79-2

Usage

Uses

Used in Pharmaceutical Research and Medicinal Chemistry:
1H-Pyrrolo[3,2-b]pyridine, 2,3-dihydrois used as a building block for the synthesis of various biologically active molecules, contributing to the development of new drugs. Its unique structure and properties make it a valuable component in the creation of pharmaceutical compounds with potential therapeutic applications.
Used in Analytical Chemistry and Bioimaging:
1H-Pyrrolo[3,2-b]pyridine, 2,3-dihydrois used as a fluorescent probe in analytical chemistry and bioimaging. Its fluorescent properties allow for the detection and visualization of specific biological processes or molecules, aiding in research and diagnostic applications.

Upstream product

• 1018950-15-6 1H-pyrrolo[3,2-b]pyridine-1-carboxylic acid 1,1-dimethylethyl ester 
• 295327-27-4 ethyl 2-(3-amino-pyridin-2-yl)-acetate 
• 1254360-67-2 tert-butyl 2,3-dihydro-1H-pyrrolo[3,2-b]pyridine-1-carboxylate 
• 1338219-71-8 2-{3-[(tert-butoxycarbonyl)amino]pyridin-2-yl}ethyl methanesulfonate 
• 1260802-19-4 tert-butyl [2-(2-hydroxyethyl)pyridin-3-yl]carbamate 
• 918153-29-4 2-(3-aminopyridin-2-yl)ethanol 
• 178896-74-7 ethyl (3-nitropyridin-2-yl)acetate hydrochloride 
• 5470-18-8 2-Chloro-3-nitropyridine 
• 272-49-1 1H-pyrrolo[3,2-b]pyridine 
• 1443981-64-3 2,3-dihydro-1H-pyrrolo[3,2-b]pyridine hydrochloride 

Downstream Products

• 1260671-35-9 5-bromo-2,3-dihydro-1H-pyrrolo[3,2-b]pyridine 

Relevant academic research and scientific papers

NOVEL SUBSTITUTED TETRAHYDROQUINOLIN COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS

Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof (I). Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

CANCER TREATMENTS TARGETING CANCER STEM CELLS

Disclosed are compounds, methods, compositions, and kits that allow for treating cancer by, e.g., targeting cancer stem cells. In some embodiments, the cancer is colorectal cancer, gastric cancer, gastrointestinal stromal tumor, ovarian cancer, lung cancer, breast cancer, pancreatic cancer, prostate cancer, testicular cancer, or lymphoma. In some embodiments, the cancer is liver cancer, endometrial cancer, leukemia, or multiple myeloma. The compounds utilized in the disclosure are of Formula (0), (O'), and (I):

This new pharmaceutical use (6-1, 6-dihydro-2-yl) amide derivative, as the inhibitor of this preparation and AKT (PKB) phosphoenzyme

The invention relates to the novel materials of formula (I), wherein each of the substituents R, R1, R2, R3, R4 and R5 is as defined herein. The materials are useful as inhibitors of AKT(PKB) phosphorylation.

INHIBITORS OF CYTOMEGALOVIRUS

Compounds of Formula (I) wherein R1, R2, R3A, R3B, Y, Z1 and Z2 are defined herein, are useful for the treatment of cytomegalovirus disease and/or infection.

Preparation of azaindolines and benzoyl substituted azaindolines: Precursors of triazabenzo[cd]azulen-9-one PDE4 inhibitors

The syntheses of various substituted azaindolines are described. Azaindolines were identified as potential key intermediates towards new PDE4 inhibitors.

NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO

New compounds are disclosed which have utility in the treatment of a variety of metabolic related conditions in a patient. The compounds of this invention have the structure (I): wherein X1, X2, X3, X4, Y1

GPR 119 MODULATORS

Compounds of Formula (I) that modulate the activity of the G -protein-coupled receptor GPFM 19 and their uses in the treatment of diseases linked to the modulation of the G-protein-coupled receptor GPR119 in animals are described herein.